Vistagen Therapeutics Statistics
Total Valuation
VTGN has a market cap or net worth of $69.61 million. The enterprise value is -$26.18 million.
Important Dates
The next estimated earnings date is Tuesday, February 11, 2025, after market close.
| Earnings Date | Feb 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VTGN has 27.84 million shares outstanding. The number of shares has increased by 284.96% in one year.
| Current Share Class | 27.84M |
| Shares Outstanding | 27.84M |
| Shares Change (YoY) | +284.96% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 23.37% |
| Float | 18.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 86.49 |
| Forward PS | 83.39 |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.29, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.29 |
| Quick Ratio | 12.97 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -61.52% and return on invested capital (ROIC) is -42.93%.
| Return on Equity (ROE) | -61.52% |
| Return on Assets (ROA) | -39.39% |
| Return on Capital (ROIC) | -42.93% |
| Revenue Per Employee | $21,900 |
| Profits Per Employee | -$989,125 |
| Employee Count | 40 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VTGN has paid $8,000 in taxes.
| Income Tax | 8,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.70% in the last 52 weeks. The beta is 0.78, so VTGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -53.70% |
| 50-Day Moving Average | 2.81 |
| 200-Day Moving Average | 3.60 |
| Relative Strength Index (RSI) | 44.74 |
| Average Volume (20 Days) | 271,934 |
Short Selling Information
The latest short interest is 425,445, so 1.53% of the outstanding shares have been sold short.
| Short Interest | 425,445 |
| Short Previous Month | 427,512 |
| Short % of Shares Out | 1.53% |
| Short % of Float | 2.34% |
| Short Ratio (days to cover) | 1.69 |
Income Statement
In the last 12 months, VTGN had revenue of $876,000 and -$39.57 million in losses. Loss per share was -$1.31.
| Revenue | 876,000 |
| Gross Profit | 876,000 |
| Operating Income | -45.60M |
| Pretax Income | -29.36M |
| Net Income | -39.57M |
| EBITDA | -45.47M |
| EBIT | -45.60M |
| Loss Per Share | -$1.31 |
Full Income StatementBalance Sheet
The company has $97.58 million in cash and $1.79 million in debt, giving a net cash position of $95.78 million or $3.44 per share.
| Cash & Cash Equivalents | 97.58M |
| Total Debt | 1.79M |
| Net Cash | 95.78M |
| Net Cash Per Share | $3.44 |
| Equity (Book Value) | 92.97M |
| Book Value Per Share | 3.44 |
| Working Capital | 92.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.49 million and capital expenditures -$164,000, giving a free cash flow of -$33.65 million.
| Operating Cash Flow | -33.49M |
| Capital Expenditures | -164,000 |
| Free Cash Flow | -33.65M |
| FCF Per Share | -$1.21 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -5,205.59% |
| Pretax Margin | -4,515.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |